Document Detail

Perinatal circulating visfatin levels in intrauterine growth restriction.
MedLine Citation:
PMID:  17502346     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: The objective of this study was to investigate possible alterations in circulating levels of the adipocytokine visfatin in intrauterine growth-restricted and normal pregnancies, given that these groups differ considerably in fetal nutrition, body fat mass, and metabolic/endocrine mechanisms. METHODS: Serum visfatin levels were prospectively measured by enzyme immunoassay in 40 mothers and their 40 singleton term fetuses and neonates on postnatal days 1 and 4. Twenty neonates had intrauterine growth restriction (birth weight < or = 3rd customized centile, adjusted for parameters that influence growth potential), and 20 were appropriate for gestational age. RESULTS: Circulating maternal visfatin levels were significantly elevated in pregnancies with intrauterine growth restriction compared with control pregnancies with appropriate-for-gestational-age infants and negatively correlated with customized centiles in the group with intrauterine growth restriction. Postnatal day-1 and -4 visfatin levels were significantly higher in neonates with intrauterine growth restriction compared with neonates who were appropriate for gestational age. Postnatal-day-1 prefeeding insulin levels were significantly lower in neonates with intrauterine growth restriction. CONCLUSIONS: Pathologic conditions in pregnancy that lead to intrauterine growth restriction could be responsible for elevated maternal visfatin levels. Higher visfatin levels in neonates with intrauterine growth restriction may serve as an early marker with prognostic value for later development of insulin resistance or type 2 diabetes, whereas lower insulin levels may indicate reduced beta-cell mass and/or impaired beta-cell function.
Ariadne Malamitsi-Puchner; Despina D Briana; Maria Boutsikou; Evangelia Kouskouni; Demetrios Hassiakos; Demetrios Gourgiotis
Related Documents :
11788356 - Amniotic igf-i supplements improve gut growth but reduce circulating igf-i in growth-re...
24800066 - Transplacental transfer of hepatitis b neutralizing antibody during pregnancy in an ani...
1492586 - Urinary and amniotic epidermal growth factor during normal and abnormal pregnancies. a ...
16169656 - Evaluation of the maternal and umbilical vein serum sfas/sfasl system in pregnancies co...
1765956 - Curettage after midtrimester termination of pregnancy. is it necessary?
2778056 - The use of albuminar 5 as a medium supplement in clinical ivf.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2007-05-14
Journal Detail:
Title:  Pediatrics     Volume:  119     ISSN:  1098-4275     ISO Abbreviation:  Pediatrics     Publication Date:  2007 Jun 
Date Detail:
Created Date:  2007-06-04     Completed Date:  2007-07-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0376422     Medline TA:  Pediatrics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e1314-8     Citation Subset:  AIM; IM    
Neonatal Division, Second Department of Obstetrics and Gynecology, Athens University, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Markers / blood
Cytokines / blood*
Fetal Blood / metabolism
Fetal Growth Retardation / blood*,  diagnosis
Infant, Newborn
Nicotinamide Phosphoribosyltransferase
Perinatal Care* / methods
Pregnancy Complications / blood*,  diagnosis
Prospective Studies
Reg. No./Substance:
0/Biological Markers; 0/Cytokines; EC Phosphoribosyltransferase; EC phosphoribosyltransferase, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  To clean or not to clean: effect on contamination rates in midstream urine collections in toilet-tra...
Next Document:  Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ...